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The physiopathology of non-insulin-dependent diabetes mellitus is associated with a dysfunction
in the regulation of insulin secretion. The R2-adrenoceptors have been reported to be involved
in this alteration, although R2-antagonists containing an imidazoline ring may stimulate insulin
secretion independently of R2-adrenoceptor blockage. Recently, a new “imidazoline-binding
site” involved in the control of K+-ATP channels in the B cell has been proposed. In the course
of searching for new antidiabetic agents, 1-alkyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-4-ben-
zylpiperazines, 1-benzyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-4-alkylpiperazines, and 1-benzyl-
2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-4-benzylpiperazines have been designed and evaluated as
potential adrenoceptor antagonists. Pharmacological evaluation was performed in vivo using
glucose tolerance tests performed on a rat model of type II diabetes obtained by injection of a
low dose (35 mg/kg) of streptozotocin (STZ). For some compounds, binding experiments were
performed on R2 adrenoceptors and I1 and I2 imidazoline-binding sites. The biological and
physicochemical data have been combined with molecular modeling studies to establish
structure-activity relationships. The most active compound was 1-(2′,4′-dichlorobenzyl)-2-
(4′,5′-dihydro-1′H-imidazol-2′-yl)-4-methylpiperazine (7f); intraperitoneal administration (100
ímol/kg) of 7f strongly improved glucose tolerance in STZ diabetic rats. This effect seemed at
least partly mediated by a significant increase of insulin secretion. Other compounds of the
same family (7b, 16f, 23b) have also shown potent activity. We found no correlation between
in vivo antihyperglycemic properties and in vitro affinities for R2-adrenoceptors or I1, and I2
binding sites. These compounds can be considered as antihyperglycemic agents potentially
useful for treatment of type II diabetes and are currently under complementary investigation.
Introduction
Non-insulin-dependent diabetes mellitus (NIDDM) is
wide spread and is one of the most common chronic
diseases, being present in 4% of the Western World’s
population, half of whom are unaware of it. Although
the frequency of diabetes is increasing, only two classes
of oral hypoglycemic agents are available for the treat-
ment of NIDDM. For both, residual â-cell insulin
secretion is necessary for activity. The sulfonylureas,
such as tolbutamide and gliclazide, are hypoglycemic
compounds, which act mainly at the pancreas level by
stimulation of insulin secretion. Their mechanism of
action is well known.1 On the other hand, the bigu-
anides (particularly metformin) act mainly in the pres-
ence of endogenous insulin by decreasing gluconeogen-
esis and increasing peripheral utilization of glucose2-5.
For many years, development of antidiabetic drugs
has been largely focused on improvement of sulfo-
nylurea derivatives, in order to increase the efficiency
and decrease side effects6 (in particular hypoglycemic
events). Among the most promising new approaches,
some imidazoline derivatives such as midaglizole,7,8
deriglidole,9-11 and efaroxan12 were reported to be R2-
antagonists acting via stimulation of insulin secretion
and to exhibit antihyperglycemic activity in vivo. In the
past few years, further studies have shown that the
insulin-secreting potency of some imidazoline deriva-
tives was not correlated with their R2-antagonistic
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properties,13,14 and so the involvement of new putative
biological targets was suggested.
It has been proposed that some of these derivatives
could interact with imidazoline-preferring binding sites
(IPBS).15,16 There are two major subtypes of IPBS: I1,
which preferentially bind [3H]clonidine or [3H]-p-ami-
noclonidine, and I2, which preferentially bind [3H]-
idazoxan.17,18 Idazoxan was selected for molecular
modeling studies for its affinity for both R2-adrenocep-
tors and I2 IPBS, whereas its close analogue, RX 821002,
was chosen as a selective R2-antagonist.
In this paper, we report the synthesis and the
pharmacological evaluation of new antihyperglycemic
2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines having the
following general formula:
These series were designed after our studies based on
comparative analysis of electronic distribution in both
Idazoxan and RX 821002. Despite their marked anti-
hyperglycemic properties, our new compounds were
devoid of significant affinities for both the R2-adreno-
ceptors and the I1 and I2 IPBS; therefore, we decided to
evaluate all of them in vivo for their antidiabetic
activity. This was achieved using glucose tolerance
tests performed on a rat model of type II diabetes
obtained by injection of a low dose (35 mg/kg) of
streptozotocine. Structural modification was systemati-
cally carried out in order to determine the necessary
structural requirements for potent in vivo activity. For
some compounds, secretion of insulin was also evalu-
ated. Some in vitro binding experiments were per-
formed on selected analogues to investigate a potential
correlation between in vivo and in vitro studies.
Molecular Modeling and Design of These Series
As mentioned in the Introduction, idazoxan and
methoxyidazoxan (RX 821002) were initially selected for
the molecular modeling studies. Our initial purpose
was to synthesize new structures having the same
binding profile as idazoxan, i.e., affinity on both R2-
adrenoceptors and I2 binding sites (RX 821002 being a
specific R2-adrenoceptor antagonist). Consequently,
calculated 3-D electrostatic potential maps of RX 821002
and idazoxan were compared with that of PMS 81219
(compound 7f) which was one of our compounds showing
potent antihyperglycemic properties. Our hypothesis
was that the electronic distribution should be as close
as possible to idazoxan’s but not to RX 821002’s.
Concerning the potential protonation, experimental
pKa values of compounds 7b,f and idazoxan were
determined. The results (Table 1) clearly demonstrate
that the imidazoline ring is the first protonation center.
The piperazine moiety is only very slighty ionized at
the physiological pH.
Moreover, calculations were performed. Whatever the
conformation could be, the protonation energy difference
between the imidazoline and piperazine nitrogens was
higher than 25 kcal/mol.20 Here, we made an abstrac-
tion of the possible protonation at physiological pH of
the imidazoline ring in this comparison.
The 3-D electrostatic potential map is the “finger-
print” of a molecule, taking into account electronic
distribution, conformation, and volume. It is the best
correlation explaining the similarity of activities be-
tween molecules which, apparently, are structurally
different.
The conformational space of RX 821002, at the AM1
level,21 has been analyzed using complete scans of the
two dihedral angles defining the relative position of the
methoxy and imidazoline groups. At each step, the
geometry was reoptimized following the procedure
implemented in GAUSSIAN 94.21
Taking into account the optimized geometry of RX
821002, Figure 1 shows that a major electrostatic
potential takes place around one of the oxygens of the
benzodioxane ring (isocontour at -20 kcal/mol) rein-
forced by the generating effect of the oxygen of the
methoxy substituent (visible with an isocontour at -40
kcal/mol, the red lines).
The comparison between 3-D electrostatic potential
maps of idazoxan and of PMS 812 (compound 7f) is clear
(Figure 2): two negative wells appear around the
nitrogens of the imidazoline ring (as in the case of RX
821002). Moreover, two separated electrostatic regions
are positioned around the nitrogens of piperazine and






a pKavalue of the imidazoline ring. b pKa value of the less
hindered tertiary amino function of the piperazine. The basicity
of compounds was assessed by potentiometric titration in aqueous
solution.
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the oxygens of dioxane. Electrostatic potential maps of
idazoxan and PMS 812 (compound 7f) may be super-
imposable if one ignores the phenyl versus benzyl ring
locations; the distances between the aromatic rings and
the heteroatoms must be different in the phenyl and
benzyl analogues. This is the reason why we chose to
develop studies in these series.
Chemistry
Scheme 1 shows a typical total synthesis of 1-aryl-4-
alkyl-2-(2-imidazolinyl)piperazines. The condensation
of 1,4-dibenzylethylenediamine and 2,3-dibromopropi-
onic acid ethyl ester, according to Jucker et al.22 with
minor modifications, gave after acidification ethyl 1,4-
dibenzyl-2-piperazinecarboxylate hydrochloride (1). The
N-debenzylation using catalytic hydrogenolysis is faster
with the dihydrochloride salt than with the free base.
The two nitrogen atoms of 2 do not present the same
reactivity. At low temperature (-10 °C) the alkylation
with 1 equiv of triphenylmethyl chloride led to the
monosubstitution on position 4. In these conditions the
ethyl 4-(triphenylmethyl)-2-piperazinecarboxylate (3)
was obtained with a very satisfactory yield. Reaction
of 3 with 1 equiv of substituted benzyl chloride afforded
the corresponding ethyl 1-(substituted benzyl)-4-(triph-
enylmethyl)-2-piperazinecarboxylate 4. Cleavage of the
protective group in dilute HCl yielded the ethyl 1-(sub-
stituted benzyl)-2-piperazinecarboxylate 5. Alkylation
of 5was carried out by action of the suitable alkyl halide
(for alkyl * CH3) in acetone with K2CO3 and catalytic
KI (for alkyl bromide) according to the method of Jerzy
et al.23 Yields of compounds 8-11 (Scheme 1) and 20
and 21 (Scheme 2) increased using an excess of the alkyl
halide. Under the same conditions methyl iodide led
to a mixture of tertiary amine and quaternary am-
monium salt. Products 6 (Scheme 1) and 18 (Scheme
2) were then obtained using formaldehyde and formic
acid in methanol according to Icke.24
Alkylation of 2 (Scheme 2) with 1 equiv of substituted
benzyl chloride in refluxing toluene gave two esters (17
and 24) in 35% and 25% yields, respectively. These
compounds were easily separated on column chroma-
tography. Ester 24 can be prepared in a yield of 80%
using 2 equiv of benzyl chloride. All imidazolines were
prepared under the same conditions according to Neef
et al.25 with a minor modification. An excess of alumi-
num organic reagent was necessarily used in order to
avoid a mixture of open-chain amide and ring-closed
heterocycle.
Pharmacological Parameters in Vivo:
Significance and Validity
Antidiabetic properties of all the synthesized com-
pounds were quantified by their ability to improve
glucose tolerance during an intravenous glucose toler-
ance test (IVGTT) in diabetic rats. From the few
existing models, a mild diabetic experimental rat model
developed by Thibault et al.26 was chosen for our
studies. This diabetic rat presents moderate basal
hyperglycemia, glucose intolerance, and impairment of
glucose-induced insulin secretion which are the main
features in patients with NIDDM. Moderate diabetes
is obtained by iv injection of a low dose (35 mg/kg) of
streptozotocin (STZ). Two weeks later, measurement
of the basal glycemia and IVGTT was performed,
allowing the selection of animals with moderate diabe-
tes, i.e., basal glycemia comprised between 7 and 10 mM
and a ¢G ranging from 50 to 80 mM. IVGTT was then
performed following a single administration of 100 ímol/
kg of the synthesized compounds. The following pa-
rameters were taken into account: (i) G30, which is the
glycemia value at 30 min after glucose administration,
(ii) ¢G, which represents the increase in glycemia over
baseline integrated over a period of 30 min following
the glucose load, and (iii) K, which is the rate of glucose
disappearance between 5 and 30 min after glucose
administration. For some compounds, secretion of
insulin was also evaluated and expressed as ¢I which
represents the incremental plasma insulin values over
baseline integrated over a period of 30 min after the
glucose load. To correct for the slight variations in
response that appeared when glucose tolerance tests
were performed with different control diabetic rats, we
decided to express the results as a percentage (¢G*) of
variation of ¢G between treated and untreated diabetic
rats. In the same way, we defined G30*, K*, and ¢I*.
To be considered as an effective antidiabetic, com-
pounds must have high a percentage of variation for
¢G*, G30*, and K*. Results around 100% or more mean
that the parameters for the treated diabetic animals are
close to those obtained with nondiabetic control animals.
Figure 1. Electrostatic potential maps of RX 821002 isocon-
toured at -20 (green lines), -30 (yellow lines), and -40 (red
lines) kcal/mol.
Figure 2. Comparison of the electrostatic potential maps of
idazoxan (left) and compound 7f (right), the lead compound of
the series 2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine, iso-
contoured at -20 (green lines), -30 (yellow lines), and -40
(red lines) kcal/mol.
¢G* ) j¢Gtreated STZ rats - ¢Guntreated STZ rats¢Guntreated STZ rats - ¢Gcontrol rats j  100
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This is the case, among others, for 7f (PMS 812) for
which results have already been published19 and 7b for
which glycemia values of STZ-treated rats are very close
to those obtained with normal rats (Figures 3 and 4).
Compounds like 13b, which has virtually no influence
on the parameters, can be considered as inactive (Figure
5). Among the three parameters, G30, which is mea-
sured directly, is considered as the most relevant.
Results and Discussion
As previously mentioned, all the synthesized com-
pounds were evaluated via an ip administration (100
ímol/kg) in glucose tolerance tests performed on STZ
rats which exhibited moderate basal hyperglycemia and
glucose intolerance. The first tested imidazoline deriva-
tive, 7b, had a potent effect on the glycemia, which
resulted in values similar to those of nondiabetic rats
(Figure 3). This correlated very well with its effects on
the three parameters, with ¢G*, G30*, and K* values
around 100%. Analogues with substituents on the
aromatic ring of the 1-benzyl-2-(4′,5′-dihydro-1′H-imi-
dazol-2′-yl)-4-methylpiperazine were studied in order to
determine their influence on antidiabetic activity (Table
2). Substitutions by halogens or other substituents
(compounds 7b-p) may result, depending on the sub-
stitution site, in a significant increase of activity com-
pared to the nonsubstituted compound 7a. The most
potent 2-monosubstituted compound was 7b, a 2-chloro
derivative, which proved to be much more active than
the nonsubstituted 7a (¢G* andG30* values respectively
of 81% and 103% for 7b compared to 0% and 23% for
7a). Analogue 7m, which is the fluoro analogue of 7b,
exhibited almost the same potency. Monosubstitution
by other groups such as 2-methyl (7p) or 2-methoxy (7l)
resulted in lower activity, while substitution by a
trifluoromethyl (7o) gave better results, almost equiva-
lent to those of 7b (Table 2).
The substituents of this 2-monosubstituted series can
be arranged in the following order of potency as anti-
hyperglycemic agents: Cl > F > CF3 > OMe > CH3.
Compound 7b was selected for pharmacomodulation.
This consisted of varying the position of the Cl on the
benzyl moiety. Compounds 7c (3-Cl) and 7d (4-Cl) were
found to be less active than 7b. Surprisingly, substitu-
tion with a 3-methoxy (7k) gave better results than with
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derivative, was found to be the most potent compound
among the disubstituted derivatives with an activity
even higher than that of 7b. The positions of the
substituent seem to be one of the most important factors
as shown by the results of the 3,4-dichloro derivative
7h which is clearly less active than 7f. These results
indicate that electronic and steric factors of substituents
seem to be strongly involved in the activity.
Scheme 2
Figure 3. Effect of a single intraperitoneal administration
of 7b on glucose tolerance: (0) STZ rats treated with 7b, (])
untreated STZ rats, and (O) control rats. *p < 0.05, signifi-
cantly different from untreated STZ rats. 7b was given (100
ímol/kg ip) 15 min before an iv glucose load (0.5 g/kg). Plasma
glucose level (mmol/L) was decreased compared to untreated
diabetic rats and was not significantly different from the value
in normal control rats.
Figure 4. Effect of a single intraperitoneal administration
of 7f on glucose tolerance: (0) STZ rats treated with 7f, (])
untreated STZ rats, and (O) control rats. *p < 0.05, signifi-
cantly different from untreated STZ rats. 7b was given (100
ímol/kg ip) 15 min before an iv glucose load (0.5 g/kg). Plasma
glucose level (mmol/L) was decreased compared to untreated
diabetic rats and was not significantly different from the value
in normal control rats.
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Regarding the substituents on piperazine nitrogens,
replacement of the methyl by a hydrogen (12b) resulted
in a total loss of activity. Substitution with an ethyl
(13b) seemed to have only little effect, while a propyl
(14b) altered the activity completely compared to the
N-methyl derivative 7b. Surprisingly, compounds with
a branched alkyl isopropyl (15b) or isobutyl (16f)
exhibited almost the same potencies as their N-methyl
counterparts 7b,f. Introduction of a second benzyl
substituent instead of the alkyl group on the piperazine
nitrogen atom (25a,b,f) resulted in a total loss of activity
compared to the monobenzylN-alkyl analogues (7a,b,f).
Inverse analogues of the most active compounds 7b,f
and 15b were prepared by variation of the benzyl and
alkyl substituents on the piperazine nitrogens. The
activities of these 1-alkyl-2-(4′,5′-dihydro-1′H-imidazol-
2′-yl)-4-benzylpiperazine derivatives (Table 3, com-
pounds 19b,f, 23b) were in the same range for the three
parameters as that of their counterparts (Table 2).
Some compounds (7a,b,f,k,l, 14b, 16f) were also evalu-
ated for their capacity to stimulate the secretion of
insulin during IVGTT. It clearly appeared that the
most active compounds on ¢G*, G30*, and K* are also
those that strongly stimulate insulin release (7b, ¢I )
109%; 7f, ¢I ) 221%; 16f, ¢I ) 623%). Compounds less
active on glycemia parameters moderately stimulate the
secretion of insulin (7k, ¢I ) 88%; 7l, ¢I ) 60%; 14b,
¢I ) 25%; 7a, ¢I ) 16%).
The in vitro binding experiments performed with our
compounds have shown that none of them had signifi-
cant affinity (>10-6 M) for the R2-adrenoceptors or I1
and I2 IPBS. This strongly suggests that the potent
insulin-secreting properties of the synthesized com-
pounds do not involve these receptors or binding sites.
This is in agreement with an increasing number of
publications showing that R2-adrenergic antagonists are
able to stimulate insulin secretion independently of R2
or/and I1 and I2 blockage.27-35 The imidazoline deriva-
tives, and more particularly those active on insulin
secretion, may interact with a novel type of imidazoline-
preferring site located on pancreatic µ cells. Compound
7f, which proved to be our most interesting compound,
is currently under complementary pharmacological
evaluation. Further chemical modulation is in progress
to obtain more active compounds and develop structure-
activity relationships. For this purpose, we have in-
vestigated some electronic and structural characteristics
of 7f, the most interesting compound, using a molecular
modeling approach.
The imidazoline substituent placed at the 2-position
of the piperazine ring of 7f plays a major role in the
twisted conformation. In practice, four conformations
(C11, C12, C21, C22) can be located on the energy
surface depending on the hybridization of the two
nitrogens with their respective lone pair “up” or “down”.
Full geometry optimization of the four conformers has
been carried out at three levels of calculation: an
approximate AM136 method and an ab initio one using
minimal and double basis sets, MINI-1′ 37 and 6-31G.38
¢G has been computed at 298.15 K and 1 atm (Table
4). From the geometrical point of view, these conform-
ers occupy a large part of the 3-D space mainly as a
Figure 5. Effect of a single intraperitoneal administration
of 13b on glucose tolerance: (0) STZ rats treated with 13b,
(]) untreated STZ rats, and (O) control rats. *p < 0.05,
significantly different from untreated STZ rats. 13b was given
(100 ímol/kg ip) 15 min before an iv glucose load (0.5 g/kg).
Plasma glucose level (mmol/L) was not decreased compared
to untreated diabetic rats and was significantly different from
the value in normal control rats.
Table 2. Variation of the Glycemia Parameters after ip
Administration of 100 ímol/kg 1-Benzyl-2-(4′,5′-dihydro-










7a (8) H CH3 0 23 67 16
7b (5) 2-Cl CH3 81 103 98 109
7c (6) 3-Cl CH3 0 23 39
7d (4) 4-Cl CH3 0 68 110
7e (5) 2,3-Cl CH3 0 36 53
7f (8) 2,4-Cl CH3 105 112 143 221
7g (9) 2,6-Cl CH3 103 59 107
7h (7) 3,4-Cl CH3 36 47 42
7i (5) 3,5-Cl CH3 0 70 117
7j (6) 2-OCH3 CH3 47 56 39
7k (5) 3-OCH3 CH3 23 68 57 88
7l (7) 2,3-OCH3 CH3 0 58 55 60
7m (5) 2-F CH3 72 52 108
7n (5) 2,4-F CH3 102 106 97
7o (8) 2-CF3 CH3 94 64 63
7p (8) 2-CH3 CH3 24 48 81
12b (4) 2-Cl H 0 0 11
13b (4) 2-Cl ethyl 108 38 34
14b (8) 2-Cl n-propyl 0 17 37 25
15b (6) 2-Cl isopropyl 84 83 44
14f (7) 2,4-Cl n-propyl 24 80 104
16f (4) 2,4-Cl isobutyl 110 95 119 623
idazoxan (6) 8 48 79
midaglizole (6) 32 121 98
a Three-month-old male Wistar rats (250 g) treated with 35 mg/
kg iv streptozotocin. b ¢G: incremental glycemia values over
baseline integrated over 30 min after glucose (0.5 g/kg iv)
administration. c G30: glycemia value 30 min after glucose ad-
ministration. d K: rate of glucose disappearance between 5 and
30 min after glucose administration. e ¢I: incremental plasma
insulin values over baseline integrated over 30 min after glucose
administration. All results (asterisk) are expressed as a percent
of variation of the parameters between treated rats (with an ip
administration of 100 ímol/kg of the tested compound) and
untreated rats; n: number of experiments conducted with each
drug, indicated in parentheses.
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result of the relative orientation of the dichlorophenyl
group. Remarkably, the relative energy differences lie
in a very small range as noted in Table 5. This feature
can be interpreted as a high capability of the molecule
7f to adopt the most effective conformation at the
receptor site including the ability of the imidazoline to
be protonated in its biological active conformation.20
Conclusion
In conclusion, most of these 29 imidazoline derivatives
synthesized had a potent effect on po glucose tolerance,
and some of them increased significantly in vivo the
insulin secretion in mildly diabetic rats. Compounds
7b, 7f (PMS 812), and 16f had the highest potency, with
glycemia values similar to those obtained with normal
rats. These compounds do not have high affinity for R2-
adrenoceptors or the known imidazoline binding sites
I1 and I2. Possibly, the effect of 7f on the insulin
secretion results from its interaction with a novel type
of imidazoline-binding site. Molecular modeling efforts
with 7f suggest that this compound is able to adopt the
most effective conformation at the receptor site and is
characterized by high flexibility. Compound 7f belongs
to a new class of imidazoline derivatives having poten-
tial therapeutic interest in type II diabetes. In the
future, the exploration in the design of these new potent
imidazoline derivatives may allow a greater understand-
ing of the structural parameters required for activity
and may shed light on the role of imidazoline derivatives
in the regulation of insulin secretion.
Experimental Section
Molecular Modeling. For all the studied products, the
geometry has been fully optimized with respect to all the 3N
- 6 degrees of freedom. The berny algorithm of the GAUSS-
IAN 94 package20 minimizes the first derivative of the energy
function calculated either at the AM1 semiempirical level or
at the ab initio level using minimal MINI-1′ and double 6-31G
basis sets. The nature of the equilibrium structures thus
obtained as true minima is given by all the positive eigenval-
ues of the second-derivative matrix.
By opposite to rigid rotor conformational analysis, the
relaxation procedure applied for RX 821002 requires a com-
plete reoptimization of the 3N - 8 other degrees of freedom
when a bidimensional map is concerned. The electrostatic
potential maps have been calculated at the ab initio level using
the MINI-1′ basis sets with the GAUSSIAN suite of pro-
grams.20
Chemistry. General Methods. The purity of each com-
pound was checked by thin-layer chromatography on TLC
plastic sheets (silica gel 60F254, layer thickness 0.2 mm) from
Merck. Column chromatography purification was carried out
on silica gel 60 (particle size 0.063-0.200 mm) from Merck,
without any special treatment. All melting points were
determined in a digital melting point apparatus (Electrother-
mal) and are uncorrected. The structures of all compounds
were confirmed by IR and 1H NMR spectra. IR spectra were
obtained with a Pye-Unicam SP3-200 infrared spectrometer,
and 1H NMR spectra were recorded in CDCl3 on a Brucker
AC 200 spectrometer using hexamethyldisiloxane (HMDS) as
an internal standard. All elemental analyses were within
(0.4% of theoretical values.
Ethyl 1,4-Dibenzyl-2-piperazinecarboxylate Dihydro-
chloride (1). To a hot (80 °C) stirred solution of N,N ′-
dibenzylethylenediamine (72 g, 0.3 mol) and triethylamine
(100 mL, 0.72 mol) in toluene (300 mL) was added dropwise,
but rapidly, ethyl 2,3-dibromopropionate (80 g, 0.31 mol in
toluene (300 mL)). After the addition, the reaction mixture
was stirred at 80 °C for 3 h, then cooled, and filtered. The
filtrate was washed with saturated aqueous sodium hydrogen
carbonate (200 mL). The organic layer was dried over MgSO4
and the solvent removed in vacuo. The crude product was
dissolved in anhydrous EtOH (400 mL) and saturated with
HCl gas. The addition of ether gave a precipitate of 1 (100-
110 g, 81-86%) as a white powder: mp 152-154 °C; IR film
(of free base) 1735 (îCdO), 1600 and 1585 (îCdC) cm-1; 1H NMR
(of free base) ä 7.4-7.1 (10H, m, aromatic H), 4.13 (2H, q, J )
7.1 Hz, COOCH2), 3.38-3.88 (4H, m, PhCH2), 3.32-3.21,
3.05-2.95, 2.69-2.27 (7H, 3m, piperazinic H), 1.19 (3H, t, J
) 7.1Hz, CH3).
Ethyl 2-Piperazinecarboxylate Dihydrochloride (2). A
shaken suspension of 1 (40 g, 0.1 mol) and 10% Pd-C (600
mg) in anhydrous ethanol (300 mL) was treated with H2 (under
pressure) at 40 °C overnight. After an addition of water until
dissolution of 2 the reaction mixture was filtered through
Celite. The addition of ether to the filtrate gave the precipitate
2 (20-23 g, 86-91%) as a white powder: mp 195-197 °C; IR
(in paraffin oil) 3380 (îN-H), 1730 (îCdO) cm-1; 1H NMR (of free
base) ä 4.13 (2H, q, J ) 7.1 Hz, COOCH2), 3.42-3.36, 3.19-
3.11, 2.98-2.68 (7H, 3m, piperazinic H), 1.84 (2H, br s, NH),
1.21 (3H, t, J ) 7.1 Hz, CH3).
Ethyl 4-(Triphenylmethyl)-2-piperazinecarboxylate (3).
To a stirred solution of 2 (23.1 g, 0.1 mol) and triethylamine
(55 mL, 0.4 mol) in dry dichloromethane (400 mL) was added
dropwise triphenylmethyl chloride (28 g, 0.1 mol) in dry
dichloromethane (300 mL) at -10 °C. After addition, the
Table 3. Variation of the Glycemia Parameters after ip
Administration of 100 ímol/kg 4-Benzyl(or 1,4-dibenzyl)-2-(4′,5′-
dihydro-1′H-imidazol-2′-yl)piperazines to Streptozotocin Ratsa







19b (5) 2-Cl CH3 93 97 148
19f (8) 2,4-Cl CH3 34 102 152
22b (5) 2-Cl ethyl 70 50 106
23b (5) 2-Cl isopropyl 112 96 95
25a (10) H 0 33 43
25b (7) 2-Cl 0 0 36
25f (5) 2,4-Cl 0 18 22
idazoxan (6) 8 48 79
midaglizole (6) 32 121 98
a Three-month-old male Wistar rats (250 g) treated with 35 mg/
kg iv streptozotocin. b ¢G: incremental glycemia values over
baseline integrated over 30 min after glucose (0.5 g/kg iv)
administration. c G30: glycemia value 30 min after glucose ad-
ministration. d K: rate of glucose disappearance between 5 and
30 min after glucose administration. All results (asterisk) are
expressed as a percent of variation of the parameters between
treated rats (with an ip administration of 100 ímol/kg of the tested
compound) and untreated rats; n: number of experiments con-
ducted with each drug, indicated in parentheses.
Table 4a
AM1 MINI-1′ 6-31G
¢E ¢E ¢G ¢E ¢G
C11 0.000 0.000 0.000 0.000 0.000
C12 0.183 1.281 0.560 1.257 -0.284
C21 2.285 2.339 1.739 -1.099 -0.303
C22 -0.860 0.277 -0.258 1.399 0.962
a Energy values are expressed in kcal/mol. The C11 conformer
is taken as reference. Negative values correspond to more stable
conformers.
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reaction mixture was stirred overnight at -10 °C. The
reaction was stopped by addition of Na2CO3 (21 g) and water
(200 mL). The organic layer was separated, washed with
water, and dried over MgSO4. After addition of toluene (50
mL), solvents were evaporated and the crude product was
crystallized from hexane:ether (9:1, v/v) to give 26 g of a white
powder. The filtrate was purified by column chromatography
using petroleum ether:ether (7:3, v/v) as eluent giving about
6 g of 3. The total yield of this reaction was 80%: mp 112-
113 °C; IR (in paraffin oil) 1740 (îCdO), 1590 (îCdC) cm -1; 1H
NMR ä 7.7-7.05 (15H, m, aromatic H), other H gave unre-
solved signals between 4.5 and 1.1 ppm.
General Procedure for Ethyl 1-(Substituted benzyl)-
4 - (triphenylmethyl) -2 -piperazinecarboxylate
Preparation: Ethyl 1-(2′-Chlorobenzyl)-4-(triphenylm-
ethyl)-2-piperazinecarboxylate (4b). A mixture of 3 (40
g, 0.1 mol), K2CO3 (40 g), KI (4 g), and 2-chlorobenzyl chloride
(19 g, 0.12 mol) in acetone (400 mL) was stirred for 15 h at
room temperature. After filtration and evaporation of the
solvent, the residue was taken up in ether, washed with water,
and dried over MgSO4. Ether was evaporated to give the crude
product 4b which was used in the next step without purifica-
tion.
General Procedure for Ethyl 1-(Substituted benzyl)-
2-piperazinecarboxylate Preparation: Ethyl 1-(2′-Chlo-
robenzyl)-2-piperazinecarboxylate (5b). Method A: All
of the crude product 4b obtained in the previous step was
treated with acetone (600 mL) and concentrated HCl (25 mL)
for 3 h at room temperature. The solvent was removed in
vacuo; the residue was solubilized in ether and washed with
water. The aqueous layer was neutralized with a saturated
Na2CO3 solution, extracted with ether, and dried over MgSO4.
Evaporation of the solvent gave a crude product which was
purified by column chromatography using first petroleum
ether:ether (30:70, v/v) and then ether to afford 19 g (80%) of
5b as a colorless oil: IR (film) 3330 (îN-H), 1740 (îCdO), 1605,
1580 (îCdC) cm-1; 1H NMR ä 7.47-7.10 (4H, m, aromatic H),
4.15 (2H, q, J ) 7.1 Hz, COOCH2), îa ) 3.74, îb ) 3.72 (2H, q,
AB spectrum, J ) 14.5 Hz, I2/I1 ) 4.45), 3.27-3.23, 3.15-2.76,
2.34-2.25 (7H, 3m, piperazinic H), 1.60 (1H, br s, NH), 1.23
(3H, t, J ) 7.1 Hz, CH3).
Method B: The crude product 4b obtained in the last step
was solubilized in ethanol (400 mL) and satured with HCl gas.
The mixture was stirred for 3 h at room temperature; then
the solvent was removed in vacuo. The residue obtained was
taken up in ether and washed with a 2 N HCl solution. The
aqueous layer was neutralized with a saturated Na2CO3
solution and extracted with ether. Drying over MgSO4,
filtration, and evaporation of CHCl3 gave a pure colorless oil
(5b) with the same yield as in method A.
General Procedure for Ethyl 1-(Substituted benzyl)-
4-alkyl-2-piperazinecarboxylate Preparation. Method
A: Ethyl 1-(2′-Chlorobenzyl)-4-methyl-2-piperazinecar-
boxylate (6b). A mixture of 5b (28 g, 0.1 mol), 37% formal-
dehyde (12 mL, 0.16 mol), and formic acid (12 mL, 0.3 mol) in
CH3OH (120 mL) was refluxed for 20 h. After evaporation of
the solvent, the residue was taken up in ether and saturated
Na2CO3 solution was added until basic pH. The organic layer
was washed with water and dried over MgSO4, and the solvent
was removed in vacuo. The crude product was dissolved in
anhydrous EtOH (200 mL) and saturated by HCl gas. The
addition of ether gave a precipitate of 6b (32 g, 86%) as a white
powder: mp 166-168 °C; IR (film, of free base) 1745 (îCdO),
1600, 1580 (îCdC) cm-1; 1H NMR ä 7.47-7.06 (4H, m, aromatic
H), 4.15 (2H, q, J ) 7.2 Hz, COOCH2), îa ) 3.88, îb ) 3.71
(2H, q, AB spectrum, J ) 14.5 Hz, I2/I1 ) 2.33, CH2Ph), 3.38-
3.33, 3.07-2.95, 2.76-2.26 (7H, 3m, piperazinic H), 2.20 (3H,
s, NCH3), 1.22 (3H, t, J ) 7.2 Hz, CH3).
Method B: Ethyl 1-(2′-Chlorobenzyl)-4-ethyl-2-pipera-
zinecarboxylate (8b). This compound was prepared from
5b following the general procedure described for 4b, but the
solution was stirred at 35 °C for 24 h. The crude product was
purified by column chromatography using petroleum ether:
ether (80:20, 60:40, and 50:50, v/v) as eluent giving 14.6 g of
8b as a pale yellow oil. Yield was about 70%: IR (film) 1755
(îCdO), 1600, 1580 (îCdC) cm-1; 1H NMR ä ppm 7.48-7.05 (4H,
2m, aromatic H), 4.13 (2H, q, J ) 7.2 Hz, COOCH2), îa ) 3.85,
îb ) 3.69 (2H, q, AB spectrum, J ) 14.5 Hz, I2/I1 ) 2.29, CH2-
Ph), 3.37-3.33, 3.04-2.98, 2.76-2.22 (9H, 3m, piperazinic H,
NCH2-CH3), 1.21 (3H, t, J ) 7.2 Hz, COOCH2-CH3), 0.98 (3H,
t, J ) 7.2 Hz, N-CH2-CH3).
Table 5. Physical Data of 1-Aryl-4-alkyl-2-(imidazolin-2-yl)piperazines
compd X R mp (°C)a % yieldb
recrystn
solventc formula
7a H CH3 166-168 55 D C15H22N4â2HClâ2H2O
7b 2-Cl CH3 160-162 70 C C15H21ClN4â2HClâ1H2O
7c 3-Cl CH3 180-182 60 D C15H21ClN4â2HClâ1H2O
7d 4-Cl CH3 198-200 49 D C15H21ClN4â2HClâ1H2O
7e 2,3-Cl CH3 158-160 58 C C15H20Cl2N4â2HClâ1H2O
7f 2,4-Cl CH3 168-170 60 D C15H20Cl2N4â2HClâ1H2O
7g 2,6-Cl CH3 182-184 43 D C15H20Cl2N4â2HClâ1H2O
7h 3,4-Cl CH3 170-172 43 D C15H20Cl2N4â2HClâ1H2O
7i 3,5-Cl CH3 167-169 47 D C15H20Cl2N4â2HClâ1H2O
7j 2-OMe CH3 168-170 36 D C16H24N4Oâ2HClâ1H2O
7k 3-OMe CH3 178-180 38 D C16H24N4Oâ2HClâ1â5H2O
7l 2,3-OMe CH3 160-162 41 D C17H26N4O2â3HClâ2H2O
7m 2-F CH3 160-162 37 D C15H21FN4â3HClâ2H2O
7n 2,4-F CH3 166-168 34 D C15H20F2N4â2HClâ1H2O
7o 2-CF3 CH3 163-165 45 D C16H21F3N4â2HClâ1H2O
7p 2-CH3 CH3 156-158 51 D C16H24N4â2HClâ1.5H2O
12b 2-Cl H 160-162 22 C C14H19ClN4â3HClâ1H2O
13b 2-Cl C2H5 162-164 30 C C16H23ClN4â2HCl
14b 2-Cl nC3H7 160-163 74 D C17H25ClN4â3HClâ1H2O
14f 2,4-Cl nC3H7 179-181 40 B C17H24Cl2N4â2HClâ1H2O
15b 2-Cl iC3H7 155-157 54 A C17H25ClN4â2HClâ1H2O
16f 2,4-Cl iC4H9 118-120 38 D C18H26Cl2N4â2HClâ1H2O
a All compounds had decomposition. b Yields of the last step. c A, acetone; B, acetone/ethanol; C, acetone/methanol; D, dichloromethane/
hexane/methanol.
3800 Journal of Medicinal Chemistry, 1997, Vol. 40, No. 23 Rondu et al.
General Procedure for Ethyl 4-(Substituted benzyl)-
2-piperazinecarboxylate Preparation: Ethyl 4-(2′-Chlo-
robenzyl)-2-piperazinecarboxylate (17b). To a refluxing
solution of 2 (23 g, 0.1 mol) and triethylamine (55 mL, 0.40
mol) in toluene (200 mL) was added dropwise 2-chlorobenzyl
bromide (16.1 g, 0.1 mol) in toluene (200 mL). The reaction
mixture was refluxed with stirring for 1 h. After cooling, the
solution was washed with water and dried over MgSO4, and
the solvent was removed in vacuo. The residue was purified
by column chromatography using first petroleum ether:ether
(70:30, v/v) and then ether yielding 10 g (25%) of 24b and 10
g (35%) of 17b as a pale yelow oil. 17b: IR (film) 3347(îN-H),
1730 (îCdO), 1594 (îCdC) cm-1; 1H NMR ä 7.41-7.08 (4H, m,
aromatic H), 4.12 (2H, q, J ) 7.1 Hz, COOCH2), 3.56 (2H, s,
CH2Ph), 3.53-2.24 (7H, m, piperazinic H), 1.85 (1H, s, NH),
1.18 (3H, t, J ) 7.1 Hz, CH3).
General Procedure for Ethyl 4-(Substituted benzyl)-
2-piperazinecarboxylate Preparation. Method A: Ethyl
4-(2′-Chlorobenzyl)-1-methyl-2-piperazinecarboxylate
(18b). 18b was prepared via the general procedure as for 6b.
The crude product was dissolved in anhydrous ethanol (200
mL) and saturated with HCl gas. The addition of ether and
chloroform gave a precipitate of 18b (31.2 g, 89%) as a white
powder: mp 155-156.5 °C; IR (film, of the free base) 1750
(îCdO), 1600, 1580 (îCdC) cm-1; 1H NMR ä 7.39-7.08 (4H, m,
aromatic H), 4.3 (2H, q, J ) 7.1 Hz, COOCH2), 3.56 (2H, s,
CH2Ph), 3.0-2.35 (7H, m, piperazinic H), 2.29 (3H, s, NCH3),
1.19 (3H, t, J ) 7.1 Hz, CH3).
Method B: Ethyl 4-(2′-Chlorobenzyl)-1-ethyl-2-pipera-
zinecarboxylate (20b). 20b was prepared via the general
procedure as for 4b. The crude product was purified by column
chromatography using petroleum ether:ether (90:10, v/v) as
eluent giving 20b as a yelow oil: IR (film) 1745 (îCdO), 1600
(îCdC) cm-1; 1H NMR ä 7.4-7.08 (4H, m, aromatic H), 4.11
(2H, q, J ) 7.1 Hz, COOCH2), 3.55 (2H, s, CH2Ph), 3.24-2.27
(9H, m, piperazinic H, NCH2), 1.17 (3H, t, J ) 7.1 Hz,
COOCH2CH3), 1.02 (3H, t, J ) 7 Hz, NCH2CH3).
General Procedure for Ethyl 1,4-Bis(substituted ben-
zyl)-2-piperazinecarboxylate Preparation: Ethyl 1,4-Bis-
(2′-chlorobenzyl)-2-piperazinecarboxylate (24b). It was
prepared via the general procedure as for 17b using 2 equiv
of 2-chlorobenzyl bromide. The crude product was purified by
crystallization of the hydrochloride salt. After basification 26
g (80%) of 24b was obtained as a colorless oil: IR (film, of free
base) 1745 (îCdO), 1605, 1585 (îCdC) cm-1; 1H NMR ä 7.46-
7.05 (8H, m, aromatic H), 4.11 (2H, q, J ) 7.2 Hz, COOCH2),
îa ) 3.91, îb ) 3.75 (2H, q, AB spectrum, J ) 14.6 Hz, I2/I1 )
2.21, CH2Ph), 3.53 (2H, s, PhCH2), 3.39-3.35, 3.18-3.08,
2.92-2.84, 2.60-2.39 (7H, 4m, piperazinic H), 1.16 (3H, t, J
) 7.2 Hz, CH3).
General Procedure for Imidazoline Preparation: 1-(2′-
Chlorobenzyl)-4-methyl-2-(4′,5′-dihydro-1′H-imidazol-2′-
yl)piperazine (7b). Ethylenediamine (4.5 mL, 0.067 mol)
was added dropwise to a stirred solution of trimethylaluminum
(58 mL, 0.17 mol) in toluene (70 mL) at 0 °C. After the
addition, the reaction mixture was heated at 50 °C and 6b
(9.8 g, 0.033 mol) in toluene (70 mL) was gradually added. The
mixture was refluxed for 5 h (under an argon atmosphere).
After stirring at room temperature overnight, the mixture was
cooled in an ice bath and treated dropwise with water (200
mL) diluted with methanol (80 mL). After filtration and
solvent evaporation the residue was taken up in dichlo-
romethane and washed with water. The organic layer was
washed with dilute HCl, and the aqueous layer was neutral-
ized by NaHCO3 and extracted twice with ether and then with
CH2Cl2 several times. The organic layers were dried over
MgSO4, and the solvents were removed in vacuo. The residue
crystallized in hexane/ether giving 7 g (70%) of 7b as a white
powder: mp 98-99 °C; IR (in KBr) 3150 (îN-H), 1620 (îCdN)
cm-1; 1H NMR ä 7.41-7.14 (4H, m, aromatic H), 5.3 (1H, br s,
NH), îa ) 3.75, îb ) 3.39 (2H, q, AB spectrum, J ) 14 Hz,
CH2Ph), 3.79-3.38 (5H, m, imidazolinic and piperazinic H),
2.81-2.12 (6H, 3m, piperazinic H), 2.22 (3H, s, NCH3).
Compounds 7a-i,m-o gave 1H NMR spectra similar to that
of 7b. 1H NMR spectra of other compounds (particular
signals): ä 7j, 3.43 (3H, s, OCH3); 7k, 3.67 (3H, s, OCH3); 7l,
3.34 (6H, s, OCH3); 7p, 2.43 (3H, s, C6H4CH3); 12b, 3.4 (1H,
br s, piperazinic NH); 13b, 0.97 (3H, t, J ) 7.1 Hz, NCH2-
CH3); 22b, 1.01 (3H, t, J ) 7.1 Hz, NCH2CH3); 14b,f, 1.51 (2H,
m, NCH2CH2-CH3), 0.82 (3H, t, J ) 7.2 Hz, N(CH2)2CH3); 15b,
0.96 (3H, d, J ) 6.5 Hz, CHCH3); 0.95 (3H, d, J ) 6.5 Hz,
CH-CH3); 16f, 1.98 (2H, d, J ) 7.1 Hz, CH2N), 1.69-1.63 (1H,
m, CH), 0.79 (6H, d, J ) 6.5 Hz, CH-(CH3)2). The synthesized
imidazolines are listed in Tables 5 and 6.
1H NMR spectra of *1-benzyl derivative esters or imidazo-
lines (series I) gave an AB system due to the CH2 group. In
series II (**4-benzyl derivatives) these 1H signals are chemi-
cally equivalent and spectra showed a singlet. In each series,
other signals are similar.
Pharmacology. Animals and Treatments. Three-month-
old male Wistar rats (Iffa-Credo, France) weighing about 250
g were used in all the experiments. The animals were housed
in wire-bottomed cages and maintained at 21 ( 2 °C in a room
with a 12 h fixed light-dark schedule. Water and standard
laboratory chow (UAR, Villemoisson-sur-Orge, France) were
freely available.
Moderate diabetes was obtained by iv injection of a low dose
(35 mg/kg) of streptozotocin (STZ) dissolved in a citrate buffer
(Thibault et al.26) under ketamine hydrochloride anesthesia
(75 mg/kg ip; Imalgene, Me´rieux, France). These rats were
Table 6. Physical Properties of 1-Alkyl-4-aryl-2-(imidazolin-2′-yl)piperazines and 1,4-Diaryl-2-(imidazolin-2′-yl)piperazines
compd X R mp (°C)a % yieldb
crystn
solventc formula
19b 2-Cl CH3 140-142 62 F C15H21ClN4â3HClâ1H2O
19f 2,4-Cl CH3 160-162 60 D C15H20Cl2N4â2HClâ1H2O
22b 2-Cl C2H5 138-140 64 B C16H23ClN4â3HClâ1H2O
23b 2-Cl iC3H7 158-160 58 C C17H25ClN4
25a H 150-152 57 E C21H26N4
25b 2-Cl 86-88 67 A C21H24Cl2N4â3HClâ2H2O
25f 2,4-Cl 188-190 62 A C21H22Cl4N4â2HClâ1H2O
a All compounds had decomposition. b Yields of the last step. c A, acetone; B, acetone/ethanol; C, acetone/methanol; D, dichloromethane/
hexane/methanol; E, ether/hexane; F, ethanol/methanol.
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called STZ rats. Control rats received an injection of citrate
buffer under the same conditions. Glucose homeostasis and
insulin secretion were assessed by a glucose tolerance test
performed 2 weeks after STZ injection.
Intravenous Glucose Tolerance Test (IVGTT). Glucose
was dissolved in 0.9% saline and given by the saphenous vein
route (0.5 g/kg) in rats under pentobarbital anesthesia (60 mg/
kg ip; Clin-Midy, France). Blood samples were collected
sequentially from the tail veins before and 5, 10, 15, 20, and
30 min after the injection of glucose. They were then centri-
fuged, and the plasma was separated. Plasma glucose con-
centration was immediately determined in a 10 íL aliquot,
and the plasma left was kept at -20 °C until radioimmunoas-
say of insulin.
Drug Administration and Antidiabetic Activity. The
2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine derivatives were
tested by a single intraperitoneal administration at 100 ímol/
kg in the STZ rat 20 min before the IVGTT. All the compounds
were used in the form of hydrochloride salts and were water-
soluble. Antidiabetic activity of the compounds was evaluated
using two parameters: ¢G, which represents the increase in
glycemia over baseline integrated over a period of 30 min
(IVGTT) following the glucose load, and K, which is the rate
of glucose disappearance between 5 and 30 min (in the case of
IVGTT), after glucose administration. The K coefficient was
calculated only during IVGTT. Insulin secretion during
IVGTT (¢I) was calculated as the incremental plasma insulin
values over baseline integrated over 30 min after the glucose
load.
Results in Figures 3-5 are expressed as a mean ( SEM.
The significance of differences between means was evaluated
by a one-way analysis of variance (ANOVA), and results were
considered significant at p < 0.05.
Tissue and Membrane Preparation. Cerebral cortex
was obtained from whole bovine brains and homogenized in
20 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4). The
homogenate was centrifuged twice at 48000g for 25 min at 4
°C. The pellet (used for R2 binding assays) was resuspended
in a phosphate buffer (pH 7.4), flash-frozen, and stored at
-80 °C untilneeded for R2 binding assays.
Reticular nucleus from calf bulbis was homogenized in ice-
cold 50 mM Tris-HCl buffer (pH 7.7) containing 5 mM EDTA.
The homogenate was centrifuged at 500g for 10 min at 4 °C.
The pellet (P1) was resuspended in the same buffer and
centrifuged again. The combined supernatants were centri-
fuged at 50000g for 25 min at 4 °C. The resulting pellet (P2)
was resuspended in 50 mM Tris-HCl buffer (pH 7.7) containing
0.1 mM p-methanesulfonyl fluoride, incubated for 30 min at
25 °C, then centrifuged again in the same conditions, resus-
pended in 50 mM Tris-HCl (pH 7.7), flash-frozen, and stored
at -80 °C until I1 imidazoline binding assays.
Renal cortex was obtained from male New Zealand white
rabbits and homogenized in ice-cold preparation buffer (20 mM
NaHCO3) (Coupry et al.39). The homogenate was centrifuged
at 40000g for 30 min at 4 °C. The pellet was resuspended in
50 mM Tris-HCl buffer containing 0.5 mM EDTA (pH 7.4),
centrifuged again, resuspended in the same buffer, flash-
frozen, and stored at -80 °C until I2 imidazoline binding
assays.
Binding Assays. [3H]RX 821002 (48 Ci/mmol), [3H]-p-
aminoclonidine (50 Ci/mmol), and [3H]idazoxan (42 Ci/mmol)
were obtained from Amersham (Buckinghamshire, U.K.) and
phentolamine, guanabenz, tolazoline, idazoxan, yohimbine,
clonidine, naphazoline, and amiloride from Sigma (St. Louis,
MO). Radioligand binding assays with [3H]RX 821002, [3H]-
p-aminoclonidine, or [3H]idazoxan for determination of specific
binding to R2-adrenoceptors and I1 and I2 imidazoline-binding
sites, respectively, were performed by a modification of meth-
ods previously described (Coupry et al.,39 Reis et al.,40 Uhlen
and Wikberg41). Membranes were slowly thawed and diluted
to a concentration of 0.4 mg of protein/mL for renal and
cerebral cortex and 0.7 mg of protein/mL for calf bulbis.
Assays were conducted in a total volume of 525 íL in
polypropylene tubes, and each tube contained 500 íL of
membrane suspension, 20 íL of radioligand, and 5 íL of drug.
Incubation was initiated by the addition of membrane and
carried out for 45 min at 25 °C. Nonspecific binding was
defined in the presence of yohimbine (10 íM) in [3H]RX 821002
binding assays, either phentolamine (10 íM) or guanabenz (5
íM) in [3H]-p-aminoclonidine binding assays, and either
tolazoline (10 íM) or amiloride (10 íM) in [3H]idazoxan binding
assays. For each drug, six concentrations from 10-4 to 10-11
M were used in triplicate. Incubations were terminated by
vacuum filtration over Whatman GF/B glass fiber filters using
a cell harvester. The filters were washed three times with
the buffer, placed in scintillation vials, covered with 2 mL of
scintillation cocktail (Pico-Fluor, Packard Instrument), and
counted (Packard 2000 CA). Protein was assayed by the
Bradford method.
Binding results were analyzed by linear regression, and the
curves were obtained with Graph PAD program (Institute for
Scientific Information, Philadelphia, PA). Ki was calculated
with the Cheng-Prusoff equation.
Analytical Methods. Plasma glucose was determined
using a glucose analyzer (Beckman Inc, Fullerton, CA).
Plasma immunoreactive insulin (IRI) concentration was de-
termined with a radioimmunoassay kit (CEA, Gif-sur-Yvette,
France). The lower limit of the assay was 19.5 pmol/L with a
coefficient of variation within and between assays of 6%.
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